Literature DB >> 28692545

Selection of women at risk for cervical cancer in an HIV-infected South African population.

Marjolein Van Zummeren1, Wieke W Kremer, Matthys C Van Aardt, Erika Breytenbach, Karin L Richter, Lawrence Rozendaal, Birgit I Witte, Lise M A De Strooper, Albertus T Hesselink, Daniëlle A M Heideman, Peter J F Snijders, Renske D M Steenbergen, Greta Dreyer, Chris J L M Meijer.   

Abstract

OBJECTIVE: Cervical cancer is the leading cause of cancer-related death in women in South Africa. This study evaluates DNA methylation levels in cervical (pre)cancer and aims to assess the value of high-risk human papillomavirus (hrHPV) testing and methylation analysis, alone or in combination, on physician-taken cervical scrapes to detect cervical cancer, and cervical intraepithelial neoplasia grade 3 (CIN3) in an HIV-infected South African population.
DESIGN: Prospective observational multicentre cohort study.
METHODS: Women from a cohort of women living with HIV (n = 355) and a referral cohort (n = 109, 60% HIV seropositive) were included. Cervical scrapes were collected for hrHPV testing and methylation analysis of cell adhesion molecule 1, T-lymphocyte maturation-associated protein, and microRNA124-2 genes. Histologic endpoints were available for all participants. Performance for detection of CIN3 or worse (CIN3+) was determined in the cohort of women living with HIV and different testing strategies were compared.
RESULTS: HrHPV and methylation positivity rates increased with severity of cervical disease in the two study cohorts, each reaching 100% in samples of women with carcinoma. HrHPV testing showed a sensitivity for CIN3+ of 83.6%, at a specificity of 67.7%. Methylation analysis showed a comparable CIN3+ sensitivity of 85.2%, but a significantly lower specificity of 49.6%. HrHPV testing with reflex methylation analysis showed a CIN3+ sensitivity of 73.8%, at a specificity of 81.5%.
CONCLUSION: In this HIV-infected South African population, stratifying hrHPV-positive women with reflex methylation analysis detects all cervical carcinomas and yields an acceptable sensitivity and specificity for CIN3+.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28692545     DOI: 10.1097/QAD.0000000000001583

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis.

Authors:  Helen Kelly; Yolanda Benavente; Miquel Angel Pavon; Silvia De Sanjose; Philippe Mayaud; Attila Tibor Lorincz
Journal:  Br J Cancer       Date:  2019-10-16       Impact factor: 7.640

2.  Detection of hypermethylated genes as markers for cervical screening in women living with HIV.

Authors:  Wieke W Kremer; Marjolein Van Zummeren; Putri W Novianti; Karin L Richter; Wina Verlaat; Peter Jf Snijders; Daniëlle Am Heideman; Renske Dm Steenbergen; Greta Dreyer; Chris Jlm Meijer
Journal:  J Int AIDS Soc       Date:  2018-08       Impact factor: 5.396

3.  HPV16-Related Cervical Cancers and Precancers Have Increased Levels of Host Cell DNA Methylation in Women Living with HIV.

Authors:  Wieke W Kremer; Marjolein van Zummeren; Daniëlle A M Heideman; Birgit I Lissenberg-Witte; Peter J F Snijders; Renske D M Steenbergen; Greta Dreyer; Chris J L M Meijer
Journal:  Int J Mol Sci       Date:  2018-10-23       Impact factor: 5.923

4.  The use of molecular markers for cervical screening of women living with HIV in South Africa.

Authors:  Wieke W Kremer; Marjolein van Zummeren; Erika Breytenbach; Karin L Richter; Renske D M Steenbergen; Chris J L M Meijer; Greta Dreyer
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

5.  DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals.

Authors:  Ramon P van der Zee; Carel J M van Noesel; Ivonne Martin; Timo J Ter Braak; Daniëlle A M Heideman; Henry J C de Vries; Jan M Prins; Renske D M Steenbergen
Journal:  Mol Oncol       Date:  2021-03-16       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.